MX2022015493A - Compuestos de imidazopiridazina y usos de los mismos. - Google Patents

Compuestos de imidazopiridazina y usos de los mismos.

Info

Publication number
MX2022015493A
MX2022015493A MX2022015493A MX2022015493A MX2022015493A MX 2022015493 A MX2022015493 A MX 2022015493A MX 2022015493 A MX2022015493 A MX 2022015493A MX 2022015493 A MX2022015493 A MX 2022015493A MX 2022015493 A MX2022015493 A MX 2022015493A
Authority
MX
Mexico
Prior art keywords
compounds
activity
imidazopyridazine compounds
alk2
alk2 inhibitors
Prior art date
Application number
MX2022015493A
Other languages
English (en)
Inventor
Jun Pan
Liangxing Wu
Yu Bai
Wenqing Yao
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MX2022015493A publication Critical patent/MX2022015493A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Dental Preparations (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de Fórmula (I), métodos de uso de los compuestos para inhibir la actividad de ALK2 y composiciones farmacéuticas que comprenden los compuestos. Los compuestos son útiles para tratar, prevenir o mejorar enfermedades o trastornos asociados con la actividad de ALK2, tales como el cáncer.
MX2022015493A 2020-06-12 2021-06-10 Compuestos de imidazopiridazina y usos de los mismos. MX2022015493A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063038410P 2020-06-12 2020-06-12
PCT/US2021/036839 WO2021252781A1 (en) 2020-06-12 2021-06-10 Imidazopyridazine compounds with activity as alk2 inhibitors

Publications (1)

Publication Number Publication Date
MX2022015493A true MX2022015493A (es) 2023-03-21

Family

ID=76971994

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015493A MX2022015493A (es) 2020-06-12 2021-06-10 Compuestos de imidazopiridazina y usos de los mismos.

Country Status (17)

Country Link
US (2) US11840546B2 (es)
EP (1) EP4165051A1 (es)
JP (1) JP2023530088A (es)
KR (1) KR20230025434A (es)
CN (1) CN115956081A (es)
AR (1) AR122587A1 (es)
AU (1) AU2021288107A1 (es)
BR (1) BR112022025191A2 (es)
CA (1) CA3184811A1 (es)
CL (1) CL2022003453A1 (es)
CO (1) CO2022017969A2 (es)
EC (1) ECSP22093652A (es)
IL (1) IL298248A (es)
MX (1) MX2022015493A (es)
PE (1) PE20230491A1 (es)
TW (1) TW202214660A (es)
WO (1) WO2021252781A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007426A (es) 2018-12-20 2021-09-08 Incyte Corp Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina.

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230396B1 (hu) 2000-06-28 2016-04-28 Smithkline Beecham Plc Nedves őrlési eljárás
PE20090506A1 (es) * 2007-07-26 2009-05-28 Novartis Ag DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4
WO2009050183A2 (en) 2007-10-17 2009-04-23 Novartis Ag Imidazo [1, 2-a] pyridine derivatives useful as alk inhibitors
ES2539257T3 (es) 2010-07-28 2015-06-29 Bayer Intellectual Property Gmbh Imidazo[1,2-b]piridazinas sustituidas
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
US20140171434A1 (en) 2011-01-11 2014-06-19 Bayer Pharma Aktiengessellschaft Substituted imidazopyridines and imidazopyridazines and the use thereof
EP2970311A4 (en) 2013-03-14 2016-11-23 Brigham & Womens Hospital BMP INHIBITORS AND METHODS OF USE
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
LT3377488T (lt) 2015-11-19 2023-01-10 Incyte Corporation Heterocikliniai junginiai, kaip imunomoduliatoriai
WO2017106634A1 (en) 2015-12-17 2017-06-22 Incyte Corporation N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
SI3394033T1 (sl) 2015-12-22 2021-03-31 Incyte Corporation Heterociklične spojine kot imunomodulatorji
MA44860A (fr) 2016-05-06 2019-03-13 Incyte Holdings Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4137489A1 (en) 2016-06-20 2023-02-22 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
BR112019004992A2 (pt) 2016-09-14 2019-06-04 Univ Vanderbilt inibição da sinalização de bmp, compostos, composições e usos destes
CA3036101A1 (en) 2016-09-15 2018-03-22 Armstrong World Industries, Inc. Ceiling system with air movement
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
TWI798192B (zh) 2016-12-22 2023-04-11 美商英塞特公司 免疫調節劑化合物及使用方法
MX2019007416A (es) 2016-12-22 2019-12-11 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
US20200054643A1 (en) 2017-01-18 2020-02-20 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
WO2018165569A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods
MX2021007426A (es) 2018-12-20 2021-09-08 Incyte Corp Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina.

Also Published As

Publication number Publication date
US20210388003A1 (en) 2021-12-16
AR122587A1 (es) 2022-09-21
JP2023530088A (ja) 2023-07-13
PE20230491A1 (es) 2023-03-23
TW202214660A (zh) 2022-04-16
CO2022017969A2 (es) 2023-02-27
KR20230025434A (ko) 2023-02-21
AU2021288107A1 (en) 2022-12-15
US11840546B2 (en) 2023-12-12
CL2022003453A1 (es) 2023-05-26
CN115956081A (zh) 2023-04-11
EP4165051A1 (en) 2023-04-19
ECSP22093652A (es) 2023-02-28
IL298248A (en) 2023-01-01
BR112022025191A2 (pt) 2023-03-07
WO2021252781A1 (en) 2021-12-16
CA3184811A1 (en) 2021-12-16
US20240083918A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
CR20220584A (es) Inhibidores de kras tricíclicos fusionados
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
MX2023007192A (es) Inhibidores de prmt5.
PH12020551927A1 (en) Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
MX2024004444A (es) Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).
TW200510380A (en) Mitotic kinesin inhibitors
MX2023012981A (es) Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.
PH12021551446A1 (en) Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
CR20230362A (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2022001004A (es) Inhibidores de enzimas.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.
PL1732926T3 (pl) Inhibitory kinezyn motorycznych
MX2021008667A (es) Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo.
CR20220280A (es) Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
MX2022015739A (es) Inhibidores alostericos de egfr y metodos de uso de estos.
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.